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Abstract

DEFINING A SIMPLIFIED PHARMACOPHORE FOR SIMOCYCLINONE D8
INHIBITION OF DNA GYRASE
by
LAUREN M. GASKELL
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University
Virginia Commonwealth University, 2013
Director: KEITH C. ELLIS
Assistant Professor, Department of Medicinal Chemistry

The type II topoisomerase subfamily of enzymes has been clinically targeted by the
widely used, broad-spectrum quinolone class of antibacterials. Due to emerging drugresistant strains of bacteria, the quinolones’ effectiveness is threatened. The natural
product simocyclinone D8 (SD8) has shown the ability to inhibit the type II
topoisomerase, DNA gyrase, even when mutated to be resistant to the quinolones.
In order to determine the pharmacophore required for SD8 binding to DNA gyrase, 16
compounds were synthesized. These compounds were then tested by surface plasmon
resonance for their ability to inhibit the DNA – DNA gyrase binding interaction.

ix

It was found that three compounds were able to inhibit the DNA – DNA gyrase binding
interaction, while another showed partial inhibition of the interaction. From this data, a
minimum pharmacophore was able to be determined. The pharmacophore required a
coumarin scaffold bonded to a carboxylic acid group through an approximately 15 Å
hydrocarbon linker.
Functional supercoiling assays determined that while the compounds were able to bind
the enzyme, the binding did not inhibit DNA gyrase’s ability to supercoil DNA.
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CHAPTER 1: INTRODUCTION

1.1: Introduction to the topoisomerase family of enzymes
Throughout the life cycle of a cell, its DNA must be transcribed and replicated. The
volume of the cell is too small to allow its DNA to be in a free configuration, so DNA is
stored in a compact form. The topology of the compacted DNA must be altered in order
to allow RNA and DNA polymerases access to the DNA.1 Strand separation during
transcription and replication generates supercoiling of the DNA because its double helical
structure does not allow free rotation. Positive supercoiling, or tightening of the double
helical structure, forms in front of the replication or transcription fork and negative
supercoiling, or loosening of the double helix, occurs behind the fork.2 If the positive
supercoiling is not corrected, it can stall transcription or replication, while negative
supercoiling interferes with normal DNA metabolism.
The topoisomerase family of enzymes is responsible for the transition between relaxed
and supercoiled states of DNA, as well as removing knots and catenates while
maintaining the compact, quaternary structure.

Topoisomerases act by cleaving the

phosphodiester backbone of DNA by nucleophilic attack by a catalytic tyrosine residue.
The catalytic tyrosine is then covalently linked to the phosphate of the DNA, a bond that
is easily broken at the end of the topoisomerase catalytic cycle.

The action of

topoisomerases does not change the sequence of the involved DNA.1

1

1.2 Types of Topoisomerases
In order to perform their various tasks, topoisomerases have evolved into more
specialized types that work together in the cell to keep DNA translation and replication
running smoothly.3 Type I topoisomerases were the first topoisomerases discovered.4 The
type I subfamily controls the topological state of DNA by binding to both strands of
double stranded DNA but cuts only one strand of the bound DNA.

Type I

topoisomerases can be further divided into type IA and type IB. Only the relaxation of
negative supercoiling is catalyzed by type IA topoisomerases, while both positive and
negative supercoiling can be relaxed by type IB. Type IB topoisomerases are the only
members of the larger topoisomerase family that bond to DNA at the 5’ end of the DNA
break through the tyrosine-phosphate bond.5 All other topoisomerase enzymes make the
tyrosine-phosphate bond at the 3’ end of the DNA break. An example of a type IB
topoisomerase is human DNA topoisomerase I, an enzyme that is clinically targeted by
the camptothecin derived family of drugs to combat human cancer. As of yet, there are
no therapeutic targets that are members of the type IA topoisomerase family.1

2

Figure 1. Crystal structure of yeast type II topoisomerase (PDB: 1BGW).

Type II topoisomerases bind double stranded DNA but unlike type I, type II
topoisomerases cleave both strands of the DNA. The cleavage points on the two strands
occur four base pairs away from one another and the enzymes work by opening a gate
between the two strands and passing a segment of double-stranded DNA through.6 Type
II topoisomerases require energy in the form of ATP hydrolysis to ADP.7

Type I

topoisomerases catalyze reactions that are thermodynamically favored and therefore, do
not require external energy in the form of ATP. The reactions that are catalyzed by type
II topoisomerases also require Mg(II) for rapid enzyme turnover.8

All type II

topoisomerases exist as A2B2 heterotetramers, as seen in Figure 1, where two A subunits
bind two B subunits to form the holoenzyme. In Figure 1, each of the four subunits is in
a different color. The A subunits are in green and yellow, while the fragments of the B
subunits are in orange and blue. In type II topoisomerases, the A subunit contains the
3

catalytic residues responsible for DNA cleavage and religation. The B subunit contains
the site where ATP is bound and cleaved for the energy required to drive the reaction.9
Crystal structures of type II topoisomerases show the enzymes look like a clamp with
hinges and jaws.9 Like type I topoisomerases, type II topoisomerases can be divided into
two types, type IIA and type IIB. The division between the types is based on structural
and functional differences between the enzymes.
The archetype of the type IIA topoisomerases is bacterial DNA gyrase. DNA gyrase was
discovered in 19767 and was the first topoisomerase discovered to utilize energy in the
form of ATP during catalysis.3 This enzyme is the only known topoisomerase that is able
to generate negative supercoiling as well as relaxing both positive and negative supercoils
and acting as a decatenase. The task of generating negative supercoils seems to be DNA
gyrase’s primary function in the cell.10 There is one ATPase site in each of the GyrB
subunits of the DNA gyrase heterotetramer holoenzyme. The GyrB subunit is 90 kDa
and consists of 804 amino acid residues. One catalytic tyrosine residue is at position 120
of each of the GyrA subunits. An arginine residue is also present near the catalytic
tyrosine and seems to play a role in catalysis. The Gyr A subunit weighs 97 kDa, and is
875 amino acid residues in length.9
The archetype of the type IIB topoisomerases is topoisomerase IV,11 an enzyme that was
discovered in 1990.12 Topoisomerase IV is believed to be the primary decatenase in the
cell. A decatenase unhooks the two daughter plasmids that are generated from DNA
replication during bacterial mitosis.

12

Like DNA gyrase, Topoisomerase IV can bind to

and relax both positive and negative supercoils.

Positive supercoils seem to be

topoisomerase IV’s preferential DNA topological structure to bind and relax.13
4

topoisomerase IV is a heterotetramer, as required by being a type II topoisomerase. It’s
A subunit, which is responsible for DNA stand cleavage and religation, is called ParC,
and is 84 kDa consisting of 752 amino acids. ParE is topoisomerase IV’s B subunit and
is responsible for ATP binding and hydrolysis. ParE is 70 kDa and consists of 630 amino
acids.

Topoisomerase IV and DNA gyrase share a very high level of amino acid

homology and about 40% sequence identity.1

1.3 Mechanism of Type II Topoisomerases

Figure 2. The mechanism of type II topoisomerases.9

5

The mechanism of type II topoisomerases (Figure 2) has yet to be fully deduced, but a
“two-gate mechanism” is strongly supported by numerous studies, including
crystallography. This “two-gate mechanism” was proposed by Roca and Wang in the
early 1990s while studying DNA gyrase and suggests the enzyme itself has two gates,
one used for capturing DNA to be translocated and a second used to release the
translocated DNA.14,15 A third gate is formed by the cleaved DNA and thus there are
three gates, total, that are opened or closed during the enzyme’s catalytic cycle. First is
the N-gate, which is comprised of the N-terminus of the GyrB subunit. The second gate
is the DNA-gate at the interface of GyrA, GyrB and DNA where DNA cleavage occurs.
The last gate is the known as the C-gate at the C-terminus of GyrB.
The first step of the mechanism is the formation of the DNA-gate upon DNA association
with the enzyme at the interface of the GyrA and GyrB subunits.16 About 130 base pairs
of DNA wrap in a right-handed supercoil around the enzyme.17 DNA wrapping around
the enzyme allows the T-segment of the DNA, the segment of DNA that will be passed
through the cleaved DNA, to align itself at the N-gate, prepared for translocation. The Ngate closes, trapping the T-segment of DNA, upon ATP binding in the GyrB subunit.18
Once the T-segment is trapped inside the N-Gate, the G-segment of DNA, the segment
that forms the DNA-gate, is cleaved. The cleavage sites of the double-stranded DNA
occurs four base pairs apart and results in phosphotyrosine bonds covalently attaching the
G-segment of DNA to the GyrA subunit of DNA gyrase.6 At this point in the enzymatic
cycle, ATP binding and hydrolysis stimulate the opening of the G-segment to form the
DNA gate and the passage of the T-segment through the gate. The subsequent hydrolysis
of a second ATP and release of two ADP molecules drives the opening of the N-gate,
6

reverses the DNA cleavage, and releases the DNA. The exact order and mechanisms of
these steps are still unknown. One cycle of supercoiling by DNA gyrase consumes two
molecules of ATP, and generates two negative supercoils.19,10 Mutagenesis experiments
have shown that when the ATP binding site is inactivated, DNA gyrase can catalyze the
relaxation of negative supercoils by the reverse mechanism.20 It has been observed that
the mechanism of topoisomerase IV is nearly identical to that of DNA gyrase,9 which
should not be surprising when considering the high level of homology between the two
enzymes. Topoisomerase IV prefers intermolecular reactions such as decatenation, while
DNA gyrase favors translocation of DNA intramolecularly to form supercoils.21 Despite
not being fully elucidated, there is enough known about the mechanism of type II
topoisomerases for the subfamily to be a very good target for antimicrobial drugs.

1.4 Type II Topoisomerases as Antibacterial Targets
Bacterial type II topoisomerases have many characteristics that make them excellent
targets for antibacterials. The subfamily has proven to be of critical importance in
bacterial replication and division. When the enzymatic cycle is halted while DNA is
cleaved, DNA cleavage complexes accumulate and induce cell death through signaling
pathways. Targeting type II topoisomerases has shown to be non-toxic to eukaryotic
enzymes.

Clinically used antibacterials have shown 100-fold selectivity for the

prokaryotic enzymes over eukaryotic enzymes. Lastly, type II topoisomerase inhibitors
tend to target both DNA gyrase and topoisomerase IV due to their high level of
homology.1 In addition to these characteristics, there are multiple instances during the
7

catalytic cycle that inhibitors can interrupt, such as DNA binding, formation of
phosphotyrosyl bonds between DNA and the enzyme, ATP binding and hydrolysis, as
well as T-segment translocation.22
Based on the inhibitor mechanism of action, type II topoisomerase inhibitors can be
divided into two categories: catalytic inhibitors and enzyme poisons. Catalytic inhibitors
block the activity of the enzyme. For example, a catalytic inhibitor could block the
binding of DNA to the enzyme, binding of ATP to the GyrB subunit, or could block the
DNA cleavage action of the catalytic tyrosines. Type II topoisomerase poisons work by
halting the enzyme mid-cycle by stabilization of the covalent DNA-enzyme complex.22 In
this instance, the equilibrium would shift to stimulate DNA cleavage and disfavor DNA
religation.23

The type II topoisomerase poisons are regarded, to date, as the most

effective drugs that target DNA gyrase and topoisomerase IV. This is due to the fact that
upon binding to the enzyme, the drug has the effect of increasing the number of doublestranded DNA-cleavage complexes within the cell. When the concentration of these
open-DNA complexes reaches a certain threshold, it activates pathways that promote
cellular death and therefore are cytotoxic.24

8

Figure 3. Structures of examples the four generations of quinolone antibiotics.

The most clinically successful class of antibacterials to target type II topoisomerases is
the quinolone class of antibiotics (Figure 3). The quinolone class is based on nalidixic
acid, an impurity found during the synthesis of the antimalarial chloroquine. Nalidixic
acid displayed very good antibiotic activity against E. coli, A. aerobacter, Proteus
mirabilis, and Shigella flexneri.25 Nalidixic acid and the derivative oxolinic acid have
been used clinically to treat urinary tract infections, but due to their limitation of only
being active against Gram-negative bacteria, improvements on the drug were sought.
The second generation of quinolone drugs incorporated a piperidine at the 7-position and
a fluorine atom at position 6, giving rise to the drugs ciprofloxacin and norfloxacin.
These changes between the first and second generations allowed antimicrobial effects to
be seen in Pseudomonas species as well as some Gram-positive bacteria.

Further
9

changes to the quinolones, such as bulky substitutions at the 7-position, a fluorine atom at
the 6-position, and substitution at the 8-position, gave rise to the third generation of the
class.

Members of the third generation include the antibacterials levofloxacin and

moxifloxacin. This generation has greater activity against Gram-positive bacteria, many
members of the generation are more specific to topoisomerase IV, and are more useful in
combating respiratory infections.

In the last decade, the fourth and most recent

generation of quinolone drugs was approved.

The Food and Drug Administration

approved the antibiotic gemifloxacin in 2003. Gemifloxacin has a better potency and a
broader spectrum of action than any of the previous generations.1,26

Figure 4. Crystal structure of topoisomerase IV ParC dimer–DNA complex with bound
moxifloxacin (PDB: 3FOE and 3FOF).
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The quinolone class of drugs acts as type II topoisomerase poisons. They stabilize the
cleavage complex step in the enzyme mechanism by targeting and binding to the bound
DNA27 and the GyrA or ParC subunit in DNA gyrase and topoisomerase IV, respectively.
X-ray crystal structures have shown the quinolone drug binding occurs at the site of DNA
cleavage. The drug molecules intercalate the cut DNA and the rings of the drug stack
with the nucleic acids at position +1 and -1 relative to the cuts in the DNA, as seen in
Figure 4. The intercalation of the drug stops the enzyme from being able to pull the Gsegment of DNA apart prohibiting both T-segment passage and DNA religation.28 When
enough of these cleavage complexes accumulate, the cell activates pathways, which are
not fully elucidated, which collectively cause chromosomal fragmentations and cell
death.29
Bacterial resistance to the quinolone class of drugs is mainly due to amino acid mutations
in the DNA-binding regions of both DNA gyrase and topoisomerase IV. These step-wise
mutations in the “quinolone resistance-determining region” (positions 67-106 in E. coli
DNA gyrase) give rise to a binding site that is unable to form binding interactions with
the drug. With a binding pocket with a lower affinity for the drug, the enzyme is not as
susceptible to the drug’s effect.1 There has also been evidence that mutations are
occurring at the mouth of the quinolone-binding site, blocking the site entirely.30 Other
mechanisms of resistance that have been observed are reduced drug uptake, up-regulation
of drug efflux pumps, and chemical alteration of the quinolone drug before it reaches its
target.1

11

Figure 5. Structures of selected examples of the aminocoumarin class of type II
topoisomerase inhibitors.
12

Type II topoisomerases can be inhibited through drugs that target the ATP binding site on
the GyrB or ParE subunit. This class of topoisomerase inhibitors is called the classical
aminocoumarins, with examples of this class being novobiocin, clorobiocin, and
coumermycin A1.

All members of this class are natural products isolated from

Streptomyces bacteria and have a shared hallmark structural feature, the 3-amino-4,7dihydroxycoumarin moiety, found in no other natural product. This group of compounds
have been known since the 1950s as nucleic acid synthesis inhibitors, but was found to
inhibit DNA gyrase soon after the enzyme was discovered.7 As seen in Figure 5, one of
the most notable differences between clorobiocin and novobiocin is the presence of a
chlorine atom at the coumarin’s 8-position in place of a methyl group.31 Despite having
no structural similarities with ATP, it has been found that the aminocoumarins inhibit
type II topoisomerases by competing for binding with ATP. Crystal structures have
shown the aminocoumarins’ exact binding site (Figure 6) is not the same as ATP, but
overlaps at the binding site of both the adenine ring of ATP and the L-noviosyl sugar of
the aminocoumarins, as seen in Figure 7, making the aminocoumarins competitive
inhibitors of type II topoisomerases.32 The binding of novobiocin to topoisomerase IV’s
ParE ATP binding domain can be seen in Figure 6, with the protein in green and the drug
in orange.

13

Figure 6. Crystal structure of novobiocin bound to the ATP binding domain of ParE
(PDB: 1S14).

14

Figure 7. Comparison of the structures of the aminocoumarin novobiocin, and the
endogenous ligand of GyrB, adenosine triphosphate (ATP).

Despite once being used to treat methicillin resistant Staphylococcus aureus (MRSA)
bacterial infections, the aminocoumarins have not seen the clinical success of the
quinolones. Aminocoumarin use has been limited by their toxicity to eukaryotic cells as
well as their poor solubility and bioavailability.33

Toxicity of drugs that target an

enzyme’s ATP site is expected since the structure of the ATP-binding site is highly
conserved across many families of enzymes.

15

Type II topoisomerases can become resistant to the aminocoumarin class of antibiotics by
step-wise mutations. The most common naturally occurring mutations are residues that
do not make contact with ATP, but are in the aminocoumarin-binding site, such as
Arg136, and Gly164, (E. coli numbering).32

A site directed mutagenesis study

considered various mutations, both naturally occurring and unnatural, and found that the
majority of mutations in the aminocoumarin-binding site gave rise to an enzyme with
reduced or no biological activity. This shows that mutation-based resistance is limited
since the ATP-site is critical to enzyme function.34 This class of drugs has proved very
useful to probing the ATP-binding site of type II topoisomerases and there are ongoing
efforts to make more selective, more bioavailable compounds with greater solubility and
less toxicity.1

Figure 8. Structures of GSK299423 and NXL101, examples of the NBTI class of type II
topoisomerase inhibitors.
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The third class of antibacterials that target type II topoisomerases are called the novel
bacterial

topoisomerase

inhibitors

(NBTIs).

This

class

was

pioneered

by

GlaxoSmithKline, and acts through a different mechanism than the previously discussed
antibacterials.22 The NBTIs act by stabilizing the DNA-enzyme complex before DNA
cleavage occurs. A limited amount of single-strand DNA cleavage has been seen with
members of the NBTIs, but this does not seem to be main mechanism of action.
Members of this class of antibacterials include NXL101 and GSK299423 (Figure 8),
synthetic small molecule inhibitors that are structurally different from both the
quinolones and the aminocoumarins.35, 36 While NXL101 has comparable IC50 values to
ciprofloxacin, its introduction was an improvement over clinically used drugs because
NSL101 has the ability to overcome ciprofloxacin resistance.36 GSK299423, a newer
NBTI, is 2000-fold more potent of an inhibitor against S. aureus DNA gyrase than
ciprofloxacin, with an IC50 of 14±5 nM. In the same study, ciprofloxacin’s IC50 was
31±10 µM.35
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Figure 9. Crystal structure of GSK299423 bound to the GyrA dimer-DNA complex
(PDB: 2XCS).

The crystal structure of GSK299423 and the S. aureus fusion protein GyrB27-A56 have
shown the binding site of this drug is in between the two GyrA subunits, blocking the
opening of the G-segment of DNA and subsequent passage of the T-segment.35 This can
easily be seen in Figure 9, where the red drug molecule is intercalating the DNA bound to
the blue and green GyrA dimer. The crystal structure of NXL101 and E. Coli GyrA also
shows NXL101 binding near the binding site of the quinolones, but does not share any
amino acid residue contacts with the quinolone class. The solved crystal structures
support the experimental findings that the NBTIs maintain antibacterial activity against
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strains of bacteria resistant to quinolones.35,36 The compound NXL101 was in clinical
trials, but further development of the drug was halted in 2008.37
Each of these three classes of antibacterials has their own limitations. The quinolones
have limited use due to increasing resistance seen in the clinic. The competitive ATP
inhibitors have selectivity and pharmacokinetic problems, and the NBTIs have yet to
have a compound successfully complete clinical trials. These problems with the existing
antibacterials that target type II topoisomerases leave much room for improvement.
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CHAPTER 2: INTRODUCTION TO SIMOCYCLINONE D8

Figure 10. Structures of simocyclinone D8 and simocyclinone D4.

A fourth class of molecules that target type II topoisomerases is the simocyclinone class.
Discovered in the year 2000, simocyclinones are natural products isolated from
Streptomyces antibioticus Tü 6040, a bacterium isolated from a soil sample from
Argentina.38

All members of this class are biosynthetic precursors to the final

fermentation product, simocyclinone D8 (SD8).39 Simocyclinone D8 (Figure 10) is a
bivalent ligand with a 3-amino-8-chloro-4,7-dihydroxycoumarin moiety at one end of the
linear molecule.40 Bonded to the amine through an amide bond is a tetraene dicarboxylic
acid linker that connects the coumarin to a D-olivose sugar. At the other end of the SD8
molecule is an angucyclic polyketide, which is connected to the D-olivose sugar through
a glycosidic linkage. Simocyclinone D4 has the same structure, but does not have the
chlorine atom at the coumarin’s 8-position. Instead, simocyclinone D4 has a hydrogen
atom occupying the 8-position of the coumarin.
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The structure of the aminocoumarins and simocyclinones are very similar. Both share a
similar coumarin moiety, with clorobiocin and SD8 both containing the same coumarin
and SD4 and novobiocin containing the same coumarin.

The structures of the

simocyclinones and aminocoumarin antibiotics differ markedly at the 7-position of the
coumarin. Aminocoumarins are bonded to a L-noviosyl sugar through an ether bond at
the 7-position of the coumarin, while simocyclinone D8 has a free hydroxyl group at the
7-position of the coumarin. Despite differences, the structural similarities between the
aminocoumarins and the simocyclinones are significant.
The biosynthetic gene cluster for simocyclinone has been sequenced and has shown to
share many similarities with the biosynthetic gene clusters for both novobiocin and
clorobiocin. One large difference between the gene clusters of the simocyclinones and
the aminocoumarin antibiotics is that the aminocoumarin genes have associated
transporter proteins and resistance genes. Producing resistance genes is important to
bacteria so it does not succumb its own biological weapon. Simocyclinone’s gene cluster
has the encoded transporter proteins, but does not include any resistance genes. The lack
of resistance genes in the simocyclinone gene cluster is interesting, since resistance genes
paired with an antibiotic hint at the bacterial target of the antibiotic produced by the
organism.41,42
First pass screens testing simocyclinone class’ antibacterial properties show both
simocyclinones D4 and D8 have antibacterial activity against Gram-positive bacteria. No
inhibition of Gram-negative bacteria was observed in the initial study. Cytostatic effects
on various human cancer cell lines were also observed when cells were treated with
simocyclinones D4 and D8.38
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Due to the simocyclinones’ structural similarities to other antibacterials that target type II
topoisomerases and preliminary evidence that SD8 functions as an antibiotic, Maxwell’s
group undertook a study to determine simocyclinone D8’s mechanism of action against
DNA gyrase isolated from E. coli. This study showed SD8 had an IC50 of ~100 nM and
was a more potent inhibitor of DNA gyrase than either novobiocin or ciprofloxacin, with
IC50 values of 250 nM and ~700 nM, respectively. Simocyclinone D4 had an IC50 of ~
450 nM. It was determined that SD8 and SD4 did not inhibit using the ATP-competitive
mechanism, because its activity was unaffected by changes in ATP concentration. ATP
cleavage was also unaffected by the presence of SD8 or SD4, indicating the
simocyclinone binding site was not on the GyrB subunit of the enzyme, despite being
very structurally similar.

Maxwell’s group also demonstrated that the simocyclinone-

binding site is very near the quinolone-binding site.

When a mutant DNA gyrase

enzyme, known for being quinolone resistant, was used in place of the wild type enzyme,
the IC50 of the simocyclinones was higher, but it was not as much of an increase as seen
for ciprofloxacin.
The next experiments examined how the simocyclinone class inhibits DNA gyrase. Data
showed that the simocyclinones inhibit the catalytic cycle before DNA is cut and may
even inhibit DNA from binding to the enzyme all together.

This indicates

simocyclinones do not have the same mechanism of action as the quinolones despite
having similar binding sites.

The simocyclinones exhibit tighter binding with the

holoenzyme of DNA gyrase than with just GyrA.

Binding more tightly to the

holoenzyme suggests that the majority of the binding site it contained within the GyrA
subunit, the entire simocyclinone-binding site spans both the GyrA and GyrB subunits.
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Despite not binding as tightly with the GyrA subunit as the holoenzyme, binding
constants showed the SD8 to GyrA binding to be in a 1:1 ratio. Simocyclinone D8 was
also tested against other topoisomerases, and was found to inhibit topoisomerase IV and
human topoisomerase II, with IC50 values of 50 µM and ~5 µM, respectively. The
inhibition of human topoisomerase II was stronger than the clinically used chemotherapy
agent, etoposide. No SD8 inhibitory effects were seen against human topoisomerase I.40
Simocyclinone D8 was tested against DNA gyrase from Staphylococcus aureus,43 a
Gram-positive bacterium that showed to be highly susceptible to SD8 in the initial
antibacterial study.38 SD8 inhibited the enzyme with an IC50 1.45 µM. Despite needing a
larger concentration of the inhibitor than against E. coli, SD8 proved to be working by
the same mechanism as published by Maxwell, et al.40 by stopping the binding of DNA to
the enzyme.

Seeing that most of the type II topoisomerase drugs target both DNA

gyrase and Topoisomerase IV, SD8 was tested against Toposiomerase IV from both S.
aureus and E. coli. It was found that SD8 had little effect on the decatenating action of
Topoisomerase IV, and it was concluded that topoisomerase IV was not the intended
target of SD8. Since SD8 was capable of inhibiting DNA gyrase from E. coli, but was
not bactericidal to the whole cell, SD8’s lack of inhibition must be stemming from
another mechanism occurring in the cell. SD8 proved to be a substrate for E. coli’s AcrB
multi-drug efflux pump. When a mutant strain of E. coli, one with no efflux pump, was
treated with SD8, the IC50 was 5 µM. This showed SD8 was pumped out of the E. coli
cells before it could bind and have an inhibitory effect on the cell.
Previous genetic studies had not been able to identify the intended target of SD8, so the
“SD8 expression profile” was studied by monitoring the changes in gene transcription
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when cells were treated with SD8. Upon treatment, the expression profile looked similar
to that of novobiocin. There was downregulation of enzymes that removed negative
supercoils, and upregulation of GyrA and GyrB genes.

There was no SOS signal

observed after dosing susceptible cells with SD8, unlike cells that had been treated with
norfloxacin, a quinolone antibiotic. The lack of an SOS signal was attributed to SD8’s
mechanism of action of blocking DNA binding instead of stabilizing the DNA-enzyme
cleavage complex. Therefore, cells are not undergoing the same type of programmed cell
death that they are with the quinolone drugs, so cell death must be attributed to another
mechanism. It was observed the nucleoid in whole cells was larger when treated with
SD8, when compared to untreated cells. This indicated unraveling of DNA due to the
lack of DNA gyrase’s control over DNA morphology. DNA unraveling would lead to
cellular death and is postulated to be SD8’s bactericidal mechanism.43
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Figure 11. Crystal structure of both modes of SD8 binding to the GyrA dimer (PDB:
2WL2).

A crystal structure of simocyclinone D8 bound to E. coli GyrA59, a truncated GyrA
subunit, was published in 2009. The structure shows the GyrA59 dimer with two bound
SD8 molecules, as the GyrA subunit contains binding sites for the aminocoumarin and
the polyketide moieties (Figure 11). Major interactions are seen between the coumarin
ring and the enzyme, as well as between the polyketide moiety and the enzyme.
Surprisingly, the tetraene diacid linker and D-olivose sugar did not play major roles in the
binding, but served only as a tether between the coumarin and polyketide. This study
proposed that SD8 binds to DNA gyrase in a “bent over” conformation. In the event that
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one molecule of SD8 binds to one heterotetramer holoenzyme of DNA gyrase, the
aminocoumarin and the polyketide sections of the molecule bridge the two GyrA
subunits.

Figure 12. Binding of SD8 to DNA gyrase, as proposed by Maxwell, et al.44

Binding of SD8 to DNA gyrase involves interactions between at least 14 amino acid
residues and the inhibitor molecule, as seen in Figure 12. Some interactions between the
enzyme and the polyketide moiety of SD8 involve bonds mediated by both waters (blue
circles, labeled “W”) and magnesium ions. Other interactions of the polyketide moiety
involve π-stacking of His80 to the benzene ring of the moiety, hydrogen bonding of
Arg32 to the epoxide, and Arg47 hydrogen bonding to a carbonyl and hydroxyl group on
the moiety. Very few interactions were seen between SD8’s tetraene linker and the
enzyme. The only interactions seen were between Arg91 and Lys42, which pi-stacked
and hydrogen bonded with the carbonyl of the amide bond connecting the coumarin to
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the linker and the nearest double bond. Arg91 also hydrogen bonded with the hydroxyl at
the 4-position of the coumarin. π-Stacking was seen between the benzyl ring of the
coumarin, Leu98 and His45. One of the more interesting interactions seen between SD8
and DNA gyrase was the halogen bond between the chlorine of SD8’s coumarin ring and
the backbone carbonyl of Gly170.

Figure 13. Structures of MDG8N2A and simocyclinone C4.

In order to determine the dependency of each end of simocyclinone D8’s binding to E.
coli DNA gyrase, the IC50 values were determined for simocyclinone C4 and
MGD8N2A.

Simocyclinone C4 (Figure 13) is a biosynthetic intermediate of SD8

lacking the 3-amino-8-chloro-4,7-dihydroxycoumarin. MGD8N2A (Figure 13) is a semisynthetic compound produced from the saponification of the ester bond connecting the
tetraene diacid and D-olivose sugar of SD8, to yield an SD8-like molecule that lacks both
the sugar and the polyketide moieties. In this study, the IC50 of parent compound SD8
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was 0.6 µM, SC4 has an IC50 of 70 µM, and MGD8N2A’s IC50 was 50 µM.44 This
shows that while the fully intact SD8 has the best inhibitory concentration, both ends are
capable of binding and inhibiting independently of one another. The coumarin with the
tetraene diacid linker proved to be a more potent inhibitor than the polyketide-sugar with
the tetraene diacid linker. When these two molecules were mixed together to test the
cooperativity of binding, there was no increased binding of either SC4 or MGD8N2A.
This could be attributed to steric interaction of the linkers. When this data is taken
together, it can be concluded that SD8’s binding affinity for DNA gyrase is due to the
coumarin and polyketide moieties being linked together.45 Because each end of SD8 can
bind independently, the structure-activity relationship study between both ends of SD8
and DNA gyrase do not need to be done together.

Individual studies of each the

coumarin and the polyketide can be undertaken.
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CHAPTER 3: A DECONSTRUCTION-RECONSTRUCTION APPROACH TO
DEFINING THE MINIMUM PHARMACOPHORE FOR SIMOCYCLINONE D8
INHIBITION OF DNA-DNA GYRASE BINDING

Simocyclinone D8’s aminocoumarin moiety is one of its more intriguing features. This
moiety is shared with the aminocoumarin class of antibiotics and has been widely studied
under the context of the antibiotic class. Our main goal was to discern which features of
SD8’s aminocoumarin and linker contribute to the binding of the molecule to DNA
gyrase and the disruption of DNA’s binding interaction.
We approached this investigation with the goal of synthesizing coumarin-based
deconstruction analogs of SD8 by incorporating a coumarin ring with few substituents.
By having a small number of substituents, we could then examine each individual
substituent’s role in binding to the enzyme. Using this method, we have the ability to
determine the pharmacophore, or the minimum coumarin scaffold required for binding to
DNA gyrase, and also be able to predict which substituents would be beneficial to
binding and what ones would detract from the binding interaction.
To achieve our goal, we concentrated on four coumarins that were either commercially
available or easily prepared: 3-amino, 3-amino-4-hydroxy, 3-amino-7-hydroxy, and 4,7dihydroxy. The main focus of the molecules we synthesized was the coumarin, so the
angucyclinone polyketide moiety of SD8 was not attached. It has been shown in binding
studies using MGD8N2A, that the coumarin and the linker are able to bind without the
polyketide moiety.44 However, the mechanism of action of MGD8N2A and its potential
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ability to disrupt the binding of DNA-to-DNA gyrase has not been explored. The base
linker length of ~15 Å was determined by molecular modeling using the crystal structure
of Gyrase and SD8 uploaded to the protein data bank by Maxwell, et al. and is the length
between the coumarin binding pocket and the mouth of the angucyclinone binding
pocket. This length translated to a saturated carbon diacid chain eight carbons in length,
not including the carbons in the carboxylic acids. Our goals in this study were to be able
to determine not only the basic SAR of the coumarin ring, but to also determine some of
the properties of the linker that are necessary for binding, such as charge, steric
limitations and the ability to form hydrogen bonds.

3.1 Synthesis of the coumarin-based deconstruction analogs of SD8
3.1.1 Synthesis of the 3-aminocoumarin derivatives
The simplest coumarin we used was 3-aminocoumarin, which was commercially
available from Aldrich. Using this coumarin, six compounds were synthesized, ranging in
complexity from the coumarin with a fatty acid chain to two coumarins connected
through an 8-carbon linker.

Since these coumarin compounds were the easiest to

synthesize, due to a lack of substituents, they were utilized to explore linker properties.
Linker length, charge, and ability to form hydrogen bonds were explored with this set of
compounds, as well as the steric limitations around the mouth of the coumarin-binding
pocket.
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Figure 14. Synthesis of 3-2

The reaction of 3-aminocoumarin with sebacic diacid chloride gave compound 3-2, in a
65% yield. Pyridine was used as both the solvent and the acid trap. These conditions
were selected after attempting the same reaction in tetrahydrofuran using triethyl amine
as an acid trap gave poor yield.

Figure 15. Synthesis of 3-3

The first step in synthesizing 3-3 was generating the diacid chloride of pimelic acid.
Pimelic acid was dissolved in dichloromethane, a drop of dimethylformamide was added
as a catalyst, followed by oxalyl chloride. Oxalyl chloride was used in place of more
commonly used thionyl chloride as we experienced coumarin stability issues when
exposed to thionyl chloride.

The pimelic diacid chloride was not isolated or

characterized, but was concentrated and added to 3-1 in pyridine, dropwise. The two-step
reaction gave 3-3, in a 26% yield. This compound was used to determine if the base
linker length of around 15 angstroms was necessary or if a shorter linker would suffice.
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Figure 16. Synthesis of 3-4

The reaction of 3-aminocoumarin with commercially available decanoyl chloride, gave 34 in a 51.5% yield. The fatty acid linker allowed us to test if a charged linker aided,
hindered, or was neutral when it came to binding.

Figure 17. Synthesis of 3-5

Reacting 2 equivalents of 3-1 with one equivalent of sebacic diacid chloride in pyridine
gave 3-5, in 21% yield. Compound 3-5 was designed to access the coumarin binding
pockets on both GyrA subunits of the Gyrase holoenzyme.

Figure 18. Synthesis of 3-6
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Commercially available p-methoxy benzoyl chloride was reacted with 3-1 to give 3-6 in a
45% yield. The p-methoxy benzene was chosen to see if an aliphatic chain was necessary
for binding, and also to determine the sterics neighboring the amide bond.

Figure 19. Synthesis of 3-7

Commercially available sebacic acid monomethyl ester was converted to the acid
chloride by dissolving the acid in dichloromethane, adding a drop of dimethyl formamide
as a catalyst, and using oxalyl chloride as the chlorinating agent. The sebacic acid
chloride monomethyl ester was concentrated, but not isolated or characterized before
being added dropwise to 3-1 dissolved in pyridine to afford 3-7 in 51.5% yield.
3.1.2: Synthesis of the 3-amino-4-hydroxycoumarin derivatives
The next coumarin we focused on was 3-amino-4-hydroxycoumarin. This coumarin
added back one of the hydroxyl substituents on the SD8 coumarin ring. The 3-amino-4hydroxycoumarin was easily accessible from 4-hydroxy-3-nitrocoumarin through a
simple hydrogenation.

These compounds were used as tools to explore both the

importance of the 4-hydroxyl group as well as the group on the end of the linker. In
order to make a direct comparison between the binding of the 3-aminocoumarin, 3amino-4-hydroxycoumarin, and MGD8N2A, the 3-amino-4-hydroxycoumarin was
coupled to the 8-carbon diacid linker. We attempted to synthesize compounds analogous
33

to each of those with the 3-aminocoumarin, but the 4-carbon of the coumarin ring proved
to be nearly as good of a nucleophile as the 3-amine group, with the 4-hydroxyl group
acting as a leaving group. It was initially thought the 4-hydroxyl group was acting as the
nucleophile, but multiple attempts to saponify the ester failed. These reactions were also
attempted using 1-ethyl-3-(3-dimethyaminopropyl)carbodiimide (EDCI) conditions to
selectively couple the carboxylic acid and the amine, but the reactions gave extremely
poor yields. Due to these issues, synthesis of analogs with the 5-carbon diacid linker, 10carbon fatty acid chain, the methyl-ester 8-carbon linker, and the p-methoxy benzoic acid
were unsuccessful. Aniline and p-hydroxyaniline were installed at the end of the linker
as simplified mimetics of the D-olivose sugar. By adding these groups on the end of the
linker, we hoped to explore the sterics, charges and electronics of the area surrounding
the sugar during SD8 binding to DNA gyrase.
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Figure 20.

Synthetic scheme of compounds 3-8, 3-9, 3-10, 3-11, and 3-12.

The first step in this synthetic scheme was to reduce the 3-nitro group of 4-hydroxy-3nitrocoumarinto an amine by catalytic hydrogenation. The hydrogenation was carried out
in acidic methanol, using 5% palladium on carbon as the catalyst. This step successfully
produced 3-8 in an 85% yield. Compound 3-8 was dissolved in pyridine and sebacic
diacid chloride was added dropwise. This reaction produced compound 3-9 in 85.6%
yield. To complete the subsequent coupling reactions, the coumarin-linker was dissolved
in dichloromethane, a drop of catalytic dimethylformamide was added, and oxalyl
chloride was used to give the acid chloride, 3-9. The acid chloride was not isolated or
characterized before being added, dropwise, to solutions of either aniline or 435

aminophenol. The reaction of the acid chloride with aniline produced 3-11 in 80% yield
and the reaction with 4-aminophenol gave 3-12 in 39% yield.

Figure 21. Synthesis of 3-13.

Two equivalents of 3-8 were dissolved in pyridine and sebacic diacid chloride was added
dropwise. Compound 3-13 was produced in 17% yield. Multiple attempts to repeat this
reaction gave very poor results.
3.1.3 Synthesis of the 3-amino-7-hydroxycoumarin analogs
The third coumarin we explored was the 3-amino-7-hydroxycoumarin. This coumarin
was not as easily accessible as the previous two coumarins. The 3-amino-7hydroxycoumarin ring was made de novo from 2,4-dihydroxybenzaldehyde and Nacetylgycine.

Like

with

the

3-amino-4-hydroxycoumarin,

the

3-amino-7-

hydroxycoumarin had some issues with coupling at the amine position. The hydroxyl
group in the 7-poistion of the ring donated electrons to the extended π-electron system,
making the carbon in the ring’s 4-position a very good nucleophile. This nucleophilicity
proved problematic as it competed with the 3-amine during the coupling reactions to give
rise to compounds with linkers attached at the 3-amine but also at the 4-postion of the
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coumarin. We attempted to use an EDCI coupling, like we did with the 3-amine-4hydroxycoumarin, and like it did with the previous coumarin, gave poor yields, if the
reaction made any progress at all.

Figure 22. Synthetic scheme of 3-14, 3-15, 3-16, 3-17, and 3-18.

To synthesize the coumarin ring the procedure used by Kudale et al.46 This procedure
dissolved 2,4-dihydroxybenzaldehyde in acetic acid and sodium acetate and N-acetyl
glycine were added. This afforded 3-14 as a pale pink solid in 24% yield. The low yield
is expected in this reaction. Next, the 7-acetyl protecting group was removed and a
benzyl group replaced it in a two-step, one-pot reaction. The acetyl group was cleaved
by the addition of potassium carbonate, and the resulting acetate was removed under
vacuum with the solvent. Acetonitrile was then used as the solvent for the benzylation.
We found if too much potassium carbonate was used, greater than two equivalents, the
amine was deprotonated and benzylated. This byproduct could not be carried forward, so
the amount of potassium carbonate needed to be below one and a half equivalents. The
next series of steps were to generate the free amine from the acetyl-protected amine. The
protected amine was secondarily protected with a Boc group. Adding the Boc group to
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the amine made the acetate easy to remove using hydrazine. The product from these two
steps (compound 3-17) was not isolated or purified because it was difficult to separate
impurities from product through crystallization or flash chromatography. The Boc group
was then cleaved using trifluoroacetic acid, giving a yield of 68.9% for the three steps.
The resulting 3-amino-7-benzyloxycoumarin was then carried on to coupling and
deprotection reactions.

Figure 23. Deprotection of 3-18 to give 3-19.

We wanted to explore if the coumarin could bind to DNA gyrase without the linker. The
benzyl protecting group of 3-18 was removed by hydrogenation in acidic methanol, using
palladium on carbon as the catalyst. The hydrogenation reaction gave 3-19 in a 92%
yield.

Figure 24. Synthetic scheme of 3-20 and 3-21.
In order to explore the binding of the 3-amino-7-hydroxycoumarin’s linker, we coupled
decanoyl chloride with 3-18, to give 3-20 in a 66% yield. The deprotection of the 7-
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hydroxyl group was done by hydrogenation carried out in acidic methanol using 5%
palladium on carbon as the catalyst. This deprotection step yielded 3-21 in 69.8% yield.

Figure 25. Synthetic scheme of 3-22 and 3-23.

Compound 3-23 was synthesized so we could make a direct comparison with 3-7 to
determine the effect of the addition of the 7-hydroxyl to the coumarin ring. To synthesize
this compound, sebacic acid monomethyl ester was dissolved in dichloromethane and a
catalytic amount of dimethylformamide was added, followed by oxalyl chloride to
generate sebacic acid chloride monomethyl ester. The acid chloride was concentrated,
but not isolated or characterized before being suspended in more dichloromethane and
added dropwise to 3-18 dissolved in pyridine. The coupled product 3-22 was isolated in
a 37% yield and was carried through the hydrogenation deprotection to give 3-23 in 27%
yield.
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3.1.4 Synthesis of 4,7-Dihydroxycoumarin
The last coumarin we explored was the 4,7-dihydroxycoumarin. This coumarin was
prepared according to the procedure detailed by Jung et al.47 We planned to install the
amine and couple this coumarin to the linker, but we observed the same issues during the
coupling reactions as seen with the 3-amino-4-hydroxycoumarin. This issue was that the
carbon in the 4-position of the coumarin acted as a nucleophile and competed with the
amine to attack the acid chloride, with the 4-hydroxyl group acting as a leaving group.
The final products had linkers at either the amine or the C4 position, or at both positions.
When synthesizing coumarin-based deconstruction SD8 analogs proved unsuccessful, we
attempted to isolate the 3-amino-4,7-dihydroxycoumarin after the final deprotection
steps. Due to the extreme polarity of the coumarin, multiple attempts at isolation were
unsuccessful. Ultimately, we decided to synthesize just the 4,7-dihydroxycoumarin and
test its ability to bind to DNA gyrase and interrupt the enzyme-DNA binding without the
linker or the amine.

40

Figure 26. Synthetic scheme of 3-26.

This scheme used 2,4-dihydroxy acetophenone as a starting material. It was first benzyl
protected in the 4-position using potassium carbonate and benzyl bromide in acetonitrile.
Benzyl protection was selective in 69% yield. Next, the coumarin ring was formed using
diethyl carbonate as the carbon source and sodium hydride as the base in 63% yield.
Hydrogenation of the benzyl group was carried out in acidic methanol using palladium on
carbon as the catalyst. This deprotection step was successful in 98% yield.

3.2 Evaluation of the activity of the compounds against DNA gyrase
The evaluation of the synthesized SD8 analogs’ ability to disrupt the DNA-DNA gyrase
binding interaction allowed us to determine the SD8 coumarin pharamacophore.

The

41

analogs ability to disrupt the DNA-DNA gyrase binding interaction was evaluated by
both surface plasmon resonance (SPR) and by enzyme inhibition studies.
3.2.1 SPR Experiments
SPR studies were used to determine if the compounds were acting by the same
mechanism as SD8, by disrupting the binding of DNA-to-DNA gyrase. The experiments
were conducted on a BioCore T200 instrument. We immobilized 5’-biotinylated DNA
on a streptavidin-functionalized chip.

Compounds were tested by first mixing the

compound with DNA gyrase. The solution contained 100 nM enzyme and 100 µM
compound. The mixture was flowed over the chip and the signal was recorded. If the
compound mixed with DNA gyrase did not bind to the enzyme and block the binding of
DNA, there was binding between DNA gyrase and the immobilized DNA. When there
was binding between DNA gyrase and the immobilized DNA, the response signal
increased to between 100 and 150 response units (RU). If the compound mixed with the
enzyme bound and blocked its binding to DNA, there was decreased DNA gyrase binding
to the DNA immobilized on the chip. When this occurred, there was no change in signal.
The purpose of conducting the SPR experiments in this manner was twofold. First, these
experiments tested the activity of the compounds, but more importantly, these
experiments tested the mechanism of action of the compounds. By pre-incubating the
compound with the enzyme, we made sure the mechanism of action of the coumarin
compound was due to binding with the enzyme, not from intercalating the DNA. The
data gathered from the SPR experiments are presented in Table 1.
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Table 1. Compound inhibition of DNA-DNA gyrase binding interaction by SPR

Compound

Inhibition Activity on DNA
gyrase by SPR

No activity
3-1
Inhibited DNA gyrase binding
to DNA
3-2
No activity
3-3
No activity
3-4
Increased DNA-DNA gyrase
binding interaction
3-5

No activity
3-6
Partial inhibition of
gyrase binding to DNA

DNA

3-7
No activity
3-8
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Inhibited DNA gyrase binding
to DNA
3-9

No activity
3-11

No activity
3-12
Increased DNA-DNA gyrase
binding interaction
3-13
No activity
3-19
No activity
3-21
Inhibited DNA gyrase binding
to DNA
3-23
No activity
3-26
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Compounds that inhibited the DNA-DNA gyrase binding interaction were 3-2, 3-7
(partial), 3-9, and 3-23 (partial). Our results allowed us to make conclusions about the
coumarin pharmacophore required for binding to DNA gyrase:
•

The compounds’ linkers do not need to be conjugated and fully saturated aliphatic
chains are tolerated.

•

Linkers shorter than 15 Å are not tolerated.

•

Substitutions on the coumarin ring are not required for binding, but are tolerated.

•

A carboxylic acid group at the end of the linker is required for full inhibition of
the DNA-DNA gyrase binding interaction.

•

Phenyl or benzyl groups are not tolerated at the end of the linker.

•

Benzoyl groups at the coumarin’s 3-amine group are not tolerated.

The results show a clear trend that allowed us to define the coumarin-based
pharmacophore of SD8’s inhibition of the DNA Gyrase-DNA binding interaction (Figure
27). The coumarin-based pharmacophore of SD8 can be defined as a required coumarin
ring connected with a carboxylic acid group through an approximately 15 Å, fully
substituted linker bonded to the coumarin with an amide bond.

Figure 27. Simocyclinone D8 coumarin pharmacophore as determined by SPR
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From this data, rough structure-activity relationships have been elucidated. Compounds
3-1, 3-8, and 3-19 have shown that more than just a substituted 3-aminocoumarin ring is
necessary for binding.

This is not surprising since the coumarins used have few

functional groups that can be used to bind to the enzyme. The linker does not need to be
rigid or conjugated, as shown by the four compounds that had inhibitory effects. A
saturated linker shorter than eight carbons is not tolerated, as shown by 3-3’s in ability to
inhibit the DNA-DNA gyrase binding interaction. The linker also must have a functional
group that has the ability to accept a hydrogen bond (3-4 and 3-21), but the hydrogen
bond donating and accepting carboxylic acid group seems to block the DNA binding
interaction better than the methyl ester group.

This was illustrated by the partial

inhibition of the binding interaction by 3-7 when compared to the total inhibition of
DNA-DNA gyrase binding interaction displayed by 3-2, the analogous compound with
the carboxylic acid. Benzyl groups are not tolerated at the end of the linker, as shown by
3-11 and 3-12. Despite 3-12 having a phenol group at the end of the linker that could
accept and donate a hydrogen bond, there was no inhibition of the binding interaction
between DNA and DNA gyrase.
Interestingly, the coumarin-linker-coumarin compounds (3-5 and 3-13) increased the
binding of DNA-to-DNA gyrase. The sensorgrams for 3-5 and 3-13 show that once the
mixture of DNA gyrase incubated with compound were flowed into the flow cell, the
response signal increased to over 200 RU. The average signal for compounds that did not
block DNA from binding to DNA gyrase was between 100 and 150 RU.

These

compounds were designed to block the DNA-DNA gyrase binding interaction by binding
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to both coumarin sites of the DNA gyrase holoenzyme, and bridging the GyrA subunits.
How these compounds are increasing the binding interaction is not fully explained by the
SPR method.
3.2.2 DNA Gyrase Functional Assay Experiments
Supercoiling assays were conducted by Dr. Hiroshi Hiasa’s group at the University of
Minnesota. This assay was used to explore if the compounds we synthesized were able to
inhibit E. coli’s DNA gyrase’s supercoiling activity. The supercoiling assay specifically
examined DNA’s ability to supercoil relaxed DNA after being treated with a compound,
by electrophoresis through an agarose gel. Relaxed DNA did not travel as far through the
gel as supercoiled DNA. Dr. Hiasa’s group found that none of the compounds we
synthesized were able to inhibit DNA gyrase’s supercoiling activity at a concentration of
100 µM. While the compounds were able to bind to the enzyme, the binding is not
enough to stop DNA gyrase’s catalytic cycle.
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CHAPTER 4: ATTEMPTS AT SYNTHESIZING 3-AMINO-8-CHLORO-4,7DIHYDROXYCOUMARIN
Once the coumarin pharamacophore was defined for SD8’s inhibition of the DNA-DNA
gyrase binding as containing the coumarin scaffold, an eight-carbon linker, and a terminal
carboxylic acid, we decided to further explore the SAR of SD8’s chlorocoumarin. The
focus of this exploration was to determine the role of chlorine at the 8-position of the
coumarin moiety. In order to be able to examine the SAR of that group, we needed to
first

develop

a

method

in

which

to

synthesis

the

3-amino-8-chloro-4,7-

dihydroxycoumarin, which has not been prepared previously by organic synthesis. Four
approaches were taken to synthesize the 3-amino-8-chloro-4,7-dihydroxycoumarin:
direct chlorination of the coumarin ring and coumarin formation from resorcinol, from
benzaldehyde, and from acetophenone.

4.1 Direct Chlorination

Figure 28. Synthetic scheme of the direct chlorination route.
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Figure 29. Synthetic products of the Chloramine T reaction. a) 3-amino-8-chloro-4hydroxy-7-methoxycoumarin, the expected product. b) 3-amino-6,8-dichloro-4-hydroxy7-methoxycoumarin, the observed over-chlorination product. c) 3-amino-6-chloro-4hydroxy-7-methoxycoumarin, a by-product.

The direct chlorination route (Figure 28) was the most attractive of the possible routes
because it had the least number of steps and started with commercially available 4hydroxy-7-methoxy-3-nitrocoumarin. The first step was to reduce the nitro to an amine,
using hydrogen gas and palladium on carbon as a catalyst.48 This reduction yielded 97%
after overnight reaction and required no further purification. The second step was to
install the chlorine at the eight position of the coumarin ring. Two methods of direct
chlorination were attempted. The first method was done in an alkaline aqueous solution
and used bleach as the chlorinating agent.49 Chlorination was not observed using these
reaction conditions, and there was poor recovery of the starting material.

A second

method was attempted using Chloramine T as the chlorinating agent and a mixture of
water and dioxane as the solvent.50 This method proved to chlorinate the coumarin with
poor regioselectivity, with the six-chlorocoumarin being one of the products. Overchlorination was seen as well, producing the 3-amino-6,8-di-chloro-4-hydroxy-7methoxycoumarin (Figure 29).

Separation of the 3-amino-8-chloro-4-hydroxy-749

methoxycoumarin from the byproducts of the reaction was not possible through
crystallization or silica gel flash chromatography. The inability to adequately purify the
desired product resulted in other synthetic routes being attempted.

4.2 Coumarin Formation from Resorcinol

Figure 30. Synthetic scheme for the resorcinol starting material.

Figure 31. Observed product from von Peckman reaction.

The second route that attempted to produce 8-chloro-4,7-dihydroxycoumarin, an
intermediate in the route to the 3-amino-3-chloro-4,7-dihydroxycoumarin, was the
coumarin formation from resorcinol using a von Peckman reaction (Figure 30).
Chlorination of resorcinol was the first step in the synthetic scheme. The conditions used
cold bleach as the chlorinating agent in an alkaline, aqueous solution,49 and afforded 57%
as an off-white solid, after silica gel flash chromatography. The subsequent step was to
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close the coumarin ring in a Von Peckman reaction, using malonyl diacid chloride.51,52
The first step of the reaction is analogous to a Fridel-Crafts acylation, where the ring acts
a nucelophile and attacks one of the acid chloride groups. The closing of the lactone ring
then occurs when the phenol group ortho to the actyl group then attacks the other acid
chloride group. Unfortunately, this second step did not occur before the Fridel-Crafts
reaction occurred again at the second acid chloride yielding the product seen in Figure
31.

4.3: Coumarin Formation from 2,4-Dihydroxybenzaldehyde

Figure 32. Synthetic route to produce the 8-chloro-4,7-dihydroxycoumarin 3-4 starting
with 2,4-dihydroxybenzaldehyde 3-11.
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A third synthetic route to obtain the 8-chloro-4,7-dihydroxycoumarin used 2,4dihydroxybenzaldehyde as the starting material, as seen in Figure 32. The first step is the
chlorination using bleach.49 Chlorination was successful with a yield of 66% of clean
product after silica gel flash chromatography purification. Next, the phenol groups were
protected with methyl groups, using potassium carbonate as a base and methyl iodide as
the methyl group donor. This step proceeded with a yield of just 54%, as there were
issues separating the mono-protected benzaldehyde from the di-protected benzaldehyde.
Oxidation of the aldehyde group to an acid was done through a Pinnick Oxidation.52
Product was isolated with an 82% yield. Coupling of the malonic acid occurred through
an acid chloride reaction, where the benzoic acid was converted to an acid chloride, and
then mixed with a mono-ethyl-protected malonic acid.53 This coupling reaction had a
yield of 78%. The final step in the synthetic route was the closing of the lactone ring of
the coumarin, and removing the methyl and BOC protecting groups in one step. This
reaction was done using boron tribromide and refluxing for 24 hours.54 Unfortunately,
this reaction did not occur, and no product or starting material could be recovered.
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Figure 33. Synthetic scheme to make the 8-chloro-4,7-dihydroxycoumarin starting with
2,4-dihydroxyacetophenone.

Figure 34. Final product seen from the lactone ring-closing step.

The last attempted synthetic route to synthesize the 8-chloro-4,7-dihydroxycoumarin used
2,4-dihyroxyacetophenone as the starting material Figure 33. Like with the previous two
routes, the first step was chlorination.49

The chlorination of the acetophenone’s 3-

position was done with bleach and occurred with a 53% yield. Next, a mono-benzyl
protection was conducted on the 4-position phenol, using potassium carbonate and benzyl
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bromide.55 The protection was successful with a 61% yield. Closing the lactone ring of
the coumarin was attempted using diethylcarbonate as the carbonate source and sodium
hydride as the base. When that reaction failed, carbodiimide, a more electron deficient
carbonate source, was used,56 and also failed. Eventually triphosgene was used as the
carbonate source. Triphosgene is a safer alternative to carbonyl dichloride, better known
as phosgene, a poison gas that has been used as a chemical warfare agent. Despite using
an extremely reactive form of carbonyl, this ring-closing step was still unsuccessful. The
product recovered was the ß-ketoacid, the intermediate of this two-step reaction (Figure
34). Further attempts to close the ß-ketoacid also failed.

4.4 Discussion
Before attempting these synthetic schemes, it was known that any substituents on the
coumarin ring highly affected its electronics due to its extended π-electron system.
Once these schemes were attempted and failed repeatedly, we reasoned the lactone ring
refused to close due to the electron withdrawing effects of the acetophenone’s 3-chlorine
substituent. Having the chlorine in the ortho-position pulled electron density out of the 2phenol, greatly reducing its nucleophilic capabilities. The same electronic effects were
seen in the reactions with recorcinol. This reduction in nucleophilicity renders the phenol
too weak of a nucleophile to attack a very electron deficient carbon, such as that in
triphosgene. We also hypothesized that if we substituted the 2,4-dihydroxy acetophenone
with iodine at the 3-position, we would have a greater chance of closing the ring. Iodine
is a softer halogen and does not have the extreme electrophilicity or electronegativity of
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chlorine. Having iodine in the 3-position may have improved coumarin binding with
DNA gyrase since iodine is known to be a better partner in halogen bonding than
chlorine. Attempts to iodate the 3-position failed so this theory could not be tested.

4.5 Future Direction
Future work on this project would include:
•

Determining additional coumarin structure – activity relationships.

•

Exploring the necessity of the amide bond between the coumarin and the linker

moieties.
•

Exploring different linker structures and geometries.

•

Synthesizing compounds with D-olivose sugar at the end of the linker to

determine its role in binding and structure - activity relationships.

4.6 Summary
In summary, we’ve designed and synthesized 12 previously unreported compounds that
are SD8 mimetics. Using these and four other compounds, we were able to establish a
basic pharmacophore for the coumarin-linker portion of Simocyclinone D8 (SD8)
through a surface plasmon resonance (SPR) assay. Bioassay data performed by Dr.
Hiasa’s group at the University of Minnesota showed none of our compounds inhibited
DNA gyrase’s ability to induce DNA supercoiling at 100 µM. We also identified at least
four pathways that will not lead to the native SD8 coumarin, 3-amino-8-chloro-4,7dihydroxycoumarin.
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Experimental Procedures

Compound 3-2
Commercially available sebacid diacid chloride (3.4 mmol , 0.915 mL) was dissolved in
15 mL of pyridine. Commercially available 3-aminocoumarin (3.1 mmol, 0.5 g) in 16
mL of pyridine was added dropwise to the acid chloride solution. The reaction was
refluxed overnight and then quenched by the addition of water (30 mL) and 6 M
hydrochloric acid (3 mL). The product was extracted into an equal volume of ethyl
acetate. The organic layer was then separated, washed with 10% copper sulfate solution,
and water until the water washes were no longer blue. The organic layer was washed
with brine, dried over sodium sulfate, and then concentrated under vacuum. Recovered
product was pure by TLC (Rf=0, 30% ethyl acetate in hexanes). This reaction gave a 65%
yield as a white solid: mp 153°C dec. IR ν (neat)/cm-1 3329.24, 3076.09, 2923.23,
2853.35; 1H NMR (400 MHz, CDCl3): ∂=1.24-1.37 (m, 12H), 1.63-1.74 (m, 2H), 2.43
(t, 2H, J=7.6, 7.6), 7.23-7.41 (m, 2H), 7.42-7.46 (m, 1H), 7.50 (dd, 1H, J=1.2, 7.6), 8.05
(s, 1H), 8.70 (s, 1H);

13

C NMR (400 MHz, CDCl3): ∂=25.25, 29.04, 29.70, 37.69,

116.34, 119.93, 123.20, 125.17, 127.78, 129.57, 149.88; HRMS C19H23NO5 Expected:
345.1576, Found: 344.1500.
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Compound 3-3
Pimelic acid (0.0994g, 0.62 mmol) was dissolved in 0.62 mL dichloromethane. One drop
of dimethylformamide was added to the solution before oxalyl chloride (0.337 mL, 3.1
mmol) was added dropwise. The reaction was stirred for one hour at room temperature
before the solvent and excess oxalyl chloride was removed by vacuum. The diacid
chloride was then redissolved in the necessary amount of dichloromethane. This solution
was added dropwise to a mixture of 3-aminocoumarin (0.1 g, 0.62 mmol) and triethyl
amine (0.26 mL, 1.9 mmol) dissolved in tetrahydrofuran (2.5 mL, 30.6 mmol). This
reaction was refluxed overnight before being quenched by the addition of water (2 mL)
and 6M hydrochloric acid (0.5 mL). The product was extracted into dichlormethane,
dried over sodium sulfate, and concentrated under vacuum.

Purification by MPLC

(CombiFlash, 0-100% ethyl acetate in hexanes) gave a white solid: mp 187-190° C, in a
26% yield. IR ν (neat)/cm-1 2470.40, 2861.20, 2925.09 (b), 3324.39; 1H NMR (400
MHz, CDCl3): ∂=1.48-1.54 (m, 6H), 1.81 (m, 2H), 2.47 (t, 2H, J=7.2, 7.6), 7.28-7.33
(m, 2H), 7.42-7.51 (m, 2H), 8.06 (s, 1H), 8.70 (s, 1H); 13C NMR (400 MHz, CDCl3): ∂
=24.82, 28.58, 37.32, 116.34, 119.89, 123.29, 123.94, 125.17, 127.80, 129.61, 149.89,
158.82, 172.16; HRMS C19H17NO5 Expected: 303.1107, Found: 302.1037.
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Compound 3-4
Commercially available decanoyl chloride (0.12 mL, 0.68 mmol) was dissolved in
pyridine (3.1 mL). To this solution, 3-aminocoumarin (0.110 g, 0.68 mmol) dissolved in
pyridine (3.1 mL) was added dropwise. The reaction was refluxed overnight before
being quenched by the addition of water (5 mL) and 6 M hydrochloric acid (0.5 mL).
The product was extracted into dichloromethane. The organic layer was then washed
with 10% copper sulfate solution, followed by water washes until the water was no
longer blue-tinted. The organic layer was dried over sodium sulfate and concentrated
under vacuum. Purification by MPLC (CombiFlash, 0-100% ethyl acetate in hexanes
gradient) gave 0.1158 g product (51.5% yield) as an off white solid: mp 106-107°C. IR ν
(neat)/cm-1 2850.48, 2920.80, 3078.91, 3336.64; 1H NMR (400 MHz, CDCl3) ∂=0.88 (t,
3H, J=6.8, 6.8), 1.27-1.38 (m,14H), 1.73 (m, 2H), 2.43 (t, 2H, J=7.6, 7.6), 7.28-7.33 (m,
2H), 7.44 (m, 1H), 7.5 (dd, 1H, J=1.2, 7.6), 8.04 (s, 1H), 8.70 (s, 1H);

13

C NMR (400

MHz, CDCl3) ∂=14.08, 22.65, 25.36, 29.17, 29.24, 29.32, 29.40, 31.84, 37.80, 116.35,
123.16, 125.17, 127.77, 129.56; HRMS C19H25NO3 Expected:

315.1834, Found:

314.1760.
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Compound 3-5
3-Aminocoumarin (0.1 g, 0.62 mmol) was dissolved in pyridine (3.1 mL) and heated to
reflux. Sebacic acid chloride (0.083 mL, 0.31 mmol) was added dropwise to the solution.
The reaction was allowed to reflux overnight before being quenched by the addition of
water (3 mL) and a few drops of 6M hydrochloric acid. Dichloromethane was added to
extract the product from the aqueous layer. The organic layer was washed with 10%
copper sulfate, followed by water washes until the wash was no longer blue. The organic
was dried over sodium sulfate and concentrated under vacuum. Purification by MPLC
(CombiFlash, 0-100% ethyl acetate in hexanes gradient) gave 31.8 mg (21% yield) of a
white solid: mp 213-217°C. Rf=0.05 in 20% ethyl acetate in hexanes. IR ν (neat)/cm-1
2853.28, 2926.80, 3076.77, 3329.31; 1H NMR (400 MHz, CDCl3) ∂ 1.35-1.40 (m, 12H),
1.68-1.75 (m, 4H), 2.43 (t, 4H, J=7.6, 7.2), 7.23-7.33 (m, 4H), 7.42-7.46 (m, 2H), 7.50
(dd, 2H, J=1.2, 7.6), 8.05 (s, 2H), 8.70 (s, 2H); 13C NMR (400 MHz, CDCl3) ∂=25.24,
29.02, 29.05, 37.68, 116.32, 119.94, 123.16, 124.01, 125.14, 127.75, 129.54, 149.90,
158.83, 172.46; HRMS C28H28N2O6 Expected: 488.1947, Found: 487.1875.
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Compound 3-6
3-Aminocoumarin (0.1 g, 0.62 mmol) was dissolved in tetrahydrofuran (2.5 mL). To the
solution, triethyl amine (0.26 mL, 1.86 mmol) was added, and the mixture was brought to
reflux. Neat p-methoxy benzoyl chloride (0.11 g, 0.62 mmol) was added dropwise, and
the reaction was allowed to reflux overnight. The reaction was quenched by the addition
of water and a few drops of 6 M hydrochloric acid.
dichloromethane.

Product was extracted into

The organic layer was separated, dried over sodium sulfate, and

concentrated under vacuum, giving an off white solid: mp 112-115°C, in a 45% yield.
Rf=0.9 in 10% methanol in dichloromethane. IR ν (neat)/cm-1 2832.68, 2932.04, 3007.39,
3361.60; 1H NMR (400 MHz, CDCl3) ∂=3.82 (s, 3H), 4.31 (s, 1H), 6.33 (s, 1H), 6.90 (d,
2H, J=8.8), 7.17-7.23 (m, 2H), 7.26-7.31 (m, 4H);

13

C NMR (400 MHz, CDCl3) ∂

=46.98, 55.32, 105.52, 114.25, 116.06, 121.65, 124.59, 125.10, 125.78. 126.92, 128.68,
129.20, 132.86, 147.99, 159.21, 159.58.

Compound 3-7
Commercially available sebacic acid methyl ester (0.134 g, 0.631 mmol) was dissolved in
dichloromethane (0.621 mL). To this solution, one drop of dimethylformamide was
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added before oxalyl chloride was added dropwise (0.337 mL, 3.1 mmol). The reaction
was allowed to stir one hour at room temperature before the solvent and excess oxalyl
chloride was removed by vacuum. The acid chloride was then dissolved in the necessary
amount of dichloromethane before being added dropwise to a solution of 3aminocoumarin (0.1 g, 0.62 mmol) and triethylamine (0.26 mL, 1.8 mmol) in
tetrahydrofuran (3.1 mL). This reaction was refluxed overnight before being quenched
by the addition of water (3 mL) and a few drops of 6 M hydrochloric acid. The product
was extracted into dichloromethane. The organic layer was washed with brine, then dried
over sodium sulfate and concentrated under vacuum. Flash silica gel chromatography
(20-50% gradient ethyl acetate in hexanes) gave 53.5 mg (24.9% yield) of a white solid:
mp 116-117°C. Rf=0.62 1:1 ethyl acetate to hexanes. IR ν (neat)/cm-1 2848.80, 2910.89,
2924.93, 3353.04; 1H NMR (400 MHz, CDCl3) ∂=1.26-1.40 (m, 8H), 1.62 (m, 2H), 1.73
(m, 2H), 2.30 (t, 2H, J=7.2, 8.0), 2.43 (t, 2H, J=7.2, 7.6), 3.67 (s, 3H), 7.30 (m, 2H), 7.427.46 (m, 1H), 7.50 (dd, 1H, J=1.2, 7.6), 8.03 (s, 1H), 8.70 (s, 1H); 13C NMR (400 MHz,
CDCl3) ∂=24.88, 25.27, 29.03, 29.06, 29.08, 34.05, 37.72, 51.37, 116.33, 123.13,
124.01, 125.14, 127.75, 129.54, 172.47, 174.19; HRMS C20H25NO5 Expected: 359.1733,
Found: 358.1664.
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Compound 3-8
4-Hydroxy-3-nitrocoumarin (1 g, 4.8 mmol) was dissolved in 75 mL 1% HCl in
methanol. This solution was cooled on ice and purged with nitrogen prior to the addition
of 5% palladium on carbon (0.16 g). The reaction vessel was sealed, placed in a Parr
shaker hydrogenator, and pressurized with hydrogen to 60 psi.

The reaction was

monitored by TLC (Rf= 0, 10% methanol in dichloromethane) until it was complete,
about 24 hours. The catalyst was filtered off and washed with methanol. The filtrate was
concentrated under vacuum to give a light yellow solid: mp 192°C, in a 92% yield. IR ν
(neat)/cm-1 2602.02 (w), 2855.92, 2926.51, 3076.80, 3327.77; 1H NMR (400 MHz,
DMSO) ∂ 7.32 (dd, 2H, J=7.2, 7.6), 7.56 (ddd, 1H, J=1.2, 7.4, 8.0), 7.96 (d, 1H, J=8.0);
13

C NMR (400 MHz, DMSO) ∂ 117.47, 122.46, 125.52, 131.42, 133.32, 135.17, 153.24,

159.54, 180.64; HRMS C9H7NO2 Expected: 177.0426, Found: 176.0353.

Compound 3-9
4-7 (0.20 g, 0.97 mmol) was dissolved in 10 mL pyridine and heated to reflux. Sebacic
diacid chloride (0.26 mL, 0.97 mmol) was added dropwise, and the reaction was allowed
to reflux overnight. The reaction was quenched by the addition of water and 1 mL 6 M
hydrochloric acid. Product was extracted into dichloromethane and washed with 10%
copper sulfate solution. The organic layer was then washed repeatedly with water until
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they no longer were blue tinted, next was dried over sodium sulfate and concentrated
under vacuum. No purification was necessary. This reaction gave a yield of 85.6% of an
off-white solid: mp 85.5-87°C. TLC of product showed smearing from the baseline in
50% acetone in hexanes. IR ν (neat)/cm-1 2850.75, 2918.20 (b); 1H NMR (400 MHz,
DMSO) ∂ 1.00-1.49 (m, 12H), 1.81 (m, 2H), 2.99 (t, 2H, J=7.2, 7.6), 7.49 (t, 1H, J=
7.2), 7.62 (d, 1H, J=8.4), 6.67-7.71 (m, 1H), 7.94 (d, 1H, J=1.6), 11.95 (s, 1H); 13C NMR
(400 MHz, DMSO) ∂ 26.57, 28.27, 28.81, 28.87, 111.67, 117.64, 121.31, 124.75,
131.39, 152.88, 156.08; HRMS C19H23NO6 Expected:

361.1525, Found:

377.1810

(compound + 1 molecule of water).

Compound 3-11
4-8 (0.05 g, 0.138 mmol) was dissolved in 0.13 mL dichlormethane. To this solution, a
drop of dimethylformamide was added, followed by oxalyl chloride (0.075 mL, 0.69
mmol). The reaction was allowed to stir an hour before the solvent was removed under
vacuum. The acid chloride was dissolved in the necessary amount of dichloromethane,
and added dropwise to a refluxing solution of aniline (0.014 mL, 0.152 mmol) and
triethyl amine (0.058 mL, 0.415 mmol) dissolved in 1 mL tetrahydrofuran. The coupling
reaction was allowed to reflux overnight before being quenched by the addition of 1 mL
water and few drops 6 M hydrochloric acid. Flash silica gel chromatography (20-100%
ethyl acetate in hexanes) gave an off-white solid: mp 123.7-124.8°C, in an 80% yield. IR
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ν (neat)/cm-1 2850.11, 2916.59, 3060.42 (w), 3322.75; 1H NMR (400 MHz, DMSO) ∂
1.25-1.4 (m, 8H), 1.58 (m, 2H), 1.81 (m, 2H), 2.28 (t, 2H, J=7.2), 2.98 (t, 2H, J=7.2), 7.0
(dd, 1H, J=72, 7.6), 7.26 (dd, 2H, J=7.6, 8.4), 7.48 (ddd, 1H, J=0.8, 7.2, 8.0), 7.58 (dd,
3H, J=7.2, 7.6), 7.68 (ddd, 1H, J=1.6, 7.2, 1.2, 7.6), 7.92 (dd, 1H, J=1.6, 8.0), 9.82 (s,
1H);

13

C NMR (400 MHz, DMSO) ∂ 25.04, 25.96, 27.42, 28.25, 28.45, 28.54, 36.35,

111.14, 117.16, 121.46, 122.85, 124.00, 125.09, 128.57, 131.71, 139.31, 152.22, 155.02,
155.40, 166.86, 171.20; HRMS C25H28N2O5 Expected: 436.1998, Found: 435.1924.

Compound 3-12
4-8 (0.05 g, 0.138 mmol) was dissolved in 0.15 mL dichlormethane. To this solution, a
drop of dimethylformamide was added, followed by oxalyl chloride (0.075 mL, 0.69
mmol). The reaction was allowed to stir an hour before the solvent was removed under
vacuum. The acid chloride was dissolved in the necessary amount of dichloromethane,
and added dropwise to a refluxing solution of 4-aminophenol (0.017 g, 0.15 mmol) and
triethyl amine (0.054 mL, 0.39 mmol) dissolved in 0.6 mL tetrahydrofuran. The coupling
reaction was allowed to reflux overnight before being quenched by the addition of 1 mL
water and few drops 6 M hydrochloric acid. Flash silica gel chromatography (0-10%
methanol in dichloromethane) gave an off-white solid: mp 181-184.7°C, in a 39% yield.
IR ν (neat)/cm-1 2850.15, 2918.39, 3295.60 (w), 3447.65 (w); 1H NMR (400 MHz,
DMSO) ∂ 1.32 (m, 9H), 1.56 (m, 1H), 1.81 (m, 2H), 2.22 (t, 2H, J=7.6), 2.99 (t, 2H,
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J=7.6), 6.65 (d, 2H, J=8.8), 7.34 (d, 2H, J=8.8), 7.49 (dd, 1H, J=8.0, 8.8), 7.93 (dd, 1H,
J=1.6, 7.6), 9.10 (s, 1H), 9.56 (s, 1H);

13

C NMR (400 MHz, DMSO) ∂ 25.17, 25.97,

27.42, 28.26, 28.59, 111.15, 114.92, 117.17, 120.77, 121.48, 125.09, 131.71, 152.23,
155.03, 166.87.

Compound 3-13
4-8 (0.1g, 0.565 mmol) was dissolved in 2.8 mL pyridine and heated to reflux. Sebacic
diacid chloride (0.076 mL, 0.282 mmol) was added dropwise and the reaction was
allowed to continue overnight. The reaction was quenched by the addition of 3 mL water
and 0.5 mL 6 M hydrochloric acid. Product was extracted with dichloromethane. The
organic layer was washed with 10% copper sulfate solution, and then water washes until
the water was no longer tinted blue. The organic layer was then dried over sodium
sulfate and concentrated under vacuum. Flash silica gel chromatography gave a pale
yellow solid in a 17% yield. IR ν (neat)/cm-1 2850.06, 2916.86 (s), 3080.12 (w), 3424.25
(b); 1H NMR (400 MHz, DMSO) ∂ 1.22-1.45 (m, 10H), 1.82 (m, 3H), 2.99 (t, 3H,
J=8.0), 7.48 (dd, 2H, J= 7.2, 7.6), 7.59 (d, 2H, J=8.4), 7.69 (ddd, 2H, J=1.6, 7.6, 8.0),
7.92 (d, 2H, J=8.0).
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Compound 3-14
Compound 3-14 was synthesized according to the procedure in Kudale, et al. Tett. Lett.
2007, 29, 5077.46 2,4-Dihydroxybenzaldehyde (10 g, 72.4 mmol) was dissolved in 362
mL acetic anhydride. Sodium acetate (23.76 g, 290 mmol) and N-acetylgycine were
added to the solution and the reaction was refluxed overnight.

The reaction was

quenched by cooling on ice and slowly adding ice-cold water. Precipitate was filter off,
and then triturated with ice-cold ethyl acetate to remove impurities. The reaction gave a
23.6% yield of a pale pink solid. 1H NMR (400 MHz, CDCl3) ∂ 2.24 (s, 3H), 2.33 (s,
3H), 7.07 (dd, 1H, J=2.0, 8.4), 7.13 (d, 1H, J=2.0), 7.50 (d, 1H, J=8.4), 8.02 (s, 1H), 8.67
(s, 1H);

13

C NMR (400 MHz, CDCl3) ∂ 21.09, 24.71, 110.04, 117.63, 119.12, 122.74,

123.57, 128.36, 150.15, 151.39, 158.49, 168.83, 169.33.

Compound 3-15
Synthesized according to the procedure in Kudale, et al. Tett. Lett. 2007, 29, 5077.46 3-14
(4 g, 15.3 mmol) was dissolved in 30.5 mL methanol. Potassium carbonate (2.75 g, 20
mmol) was added to the solution and the reaction was allowed to stir 30 minutes. The
solvent was then removed by rotary evaporation. The solids were then suspended in 77
mL acetonitrile before the addition of benzyl bromide (2 mL, 16.8 mmol). This second
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reaction was refluxed overnight.

The reaction was then diluted with water, and

neutralized with 6 M HCl. Ethyl actate was then added to precipitate the product.
Product was filtered off and rinsed with water and then dried under vacuum to give 4.69
g (99% yield) of a pale yellow solid. 1H NMR (400 MHz, CDCl3) ∂ 2.22 (s, 3H), 5.12
(s, 2H), 6.89 (d, 1H, J=2.0), 6.96 (dd, 1H, J=2.0, 8.4), 7.30-7.44 (m, 6H), 7.95 (s, 1H),
8.63 (s, 1H);

13

C NMR (400 MHz, CDCl3) ∂ 24.62, 70.56, 101.89, 113.32, 113.86,

121.69, 123.99, 127.47, 128.33, 128.65, 128.73, 135.95, 151.34, 159.00, 160.35, 169.11.

Compound 3-17
Synthesized according to the procedure in Kudale, et al. Tett. Lett. 2007, 29, 5077.46 315 (4.5 g, 14.5 mmol) was suspended in 73 mL tetrahydrofuran.

To the solution,

dimethylamino pyridine (8.89 g, 72.7 mmol) was added followed by di-tert-butyl
dicarbonate (3.18 g, 14.5 mmol). The reaction was allowed to stir until the yellow
suspension became a clear, brown-colored, solution, about 30 minutes. To the solution,
hydrazine (3.64 mL, 72.7 mmol) was added, followed by 60 mL methanol. This second
reaction was allowed to stir until the reaction became bright orange, about 20 minutes.
The solvents were then removed by rotary evaporation, and the solids dissolved in the
necessary amount of dichloromethane. The organic solution was washed with 1 M HCl,
10% copper sulfate, saturated sodium bicarbonate, and followed by a brine wash. The
organic layer was then dried over sodium sulfate and concentrated under vacuum.

1

H
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NMR (400 MHz, CDCl3) ∂ 1.53 (s, 9H), 5.11 (s, 2H), 6.89 (d, 1H, J=2.0), 6.92 (dd, 1H,
J=2.0, 8.4), 7.38 (m, 6H), 8.23 (s, 1H); 13C NMR (400 MHz, CDCl3) 28.23, 20.87, 70.52,
81.48, 101.81, 113.57, 113.73, 121.17, 122.28, 127.50, 128.12, 128.30, 128.73, 136.04,
150.88, 152.59, 158.86, 159.83.

Compound 3-18
Synthesized according to the procedure in Kudale, et al. Tett. Lett. 2007, 29, 5077.46 317 (5 g, 13.6 mmol) was dissolved in 68 mL dichloromethane.

To the solution,

trifluoroacetic acid (20.8 mL, 272 mmol) was added dropwise. The reaction was allowed
to stir over night at room temperature. Once TLC confirmed reaction had gone to
completion, the mixture was neutralized with saturated sodium bicarbonate. The organic
layer was separated from the aqueous, and dried over sodium sulfate. The organic layer
was then dried over sodium sulfate and concentrated under vacuum. Flash silica gel
chromatography (0-100% ethyl acetate in hexanes gradient) gave product with a 68.9%
yield. 1H NMR (400 MHz, CDCl3) ∂ 4.05 (broad s, 2H), 5.09 (s, 2H), 6.69 (s, 1H), 6.89
(m, 2H), 7.19 (d, 1H, J=9.2), 7.31-7.41 (m, 5H); 13C NMR (400 MHz, CDCl3) ∂ 70.47,
101.94, 112.04, 113.30, 114.65, 123.40, 125.82, 127.48, 128.19, 128.69, 136.33.150.27,
158.14.
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Compound 3-19
3-Amino-7-benzyloxycoumarin 3-18 (0.15 g, 0.561 mmol) was dissolved in 0.56 mL 1%
HCl methanol. The solution was cooled on ice and the vessel purged with nitrogen gas
before the addition of 5% palladium on carbon (0.0075 g) catalyst. The reaction vessel
was placed under vacuum, and then backfilled with 1 atm hydrogen gas. The reaction
was monitored by TLC (Rf=0.0, 1:1 ethyl acetate in hexanes). Once TLC indicated no
starting material remained, the catalyst was filtered off and rinsed with methanol. The
filtrate was concentrated under vacuum to give 92% yield an off white solid: mp 212° C
dec. IR ν (neat)/cm-1 2597.88, 2850.52 (b), 3232.68 (b); 1H NMR (400MHz, DMSO) ∂
6.68 (d, 1H, J=1.6), 6.71 (dd, 1H, J=1.6, 8.4), 7.29 (d, 1H, J=8.4), 8.28 (s, 1H); 13C NMR
(400 MHz, DMSO) ∂ 101.91, 112.89, 113.21, 114.22, 126.46, 127.69, 150.09, 157.07,
158.83; HRMS C9H7NO3 Expected: 177.0426, Found: 176.0356.

Compound 3-20
Commercially available decanoyl chloride (0.70 mL, 0.4 mmol) was dissolved in 1.75
mL pyrideine and heated. Compound 3-18 was dissolved in 1.75 mL pyridine and added
dropwise to the acid chloride solution. The reaction was refluxed overnight before being
quenched by the addition of an equal volume of water and 0.5 mL 6M hydrochloric acid.
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The product was extracted into dichloromethane and washed with 10% copper sulfate
solution, and then water until the water was no longer blue-tinted. The organic was then
dried over sodium sulfate and concentrated under vacuum.

Flash silica gel

chromatography (Rf=0.901 in 1:1 ethyl acetate in hexanes) gave 0.1145 g of an oil (66%
yield). IR ν (neat)/cm-1 2852.76, 2923.46, 2952.39 (w), 3037.51 (w), 3316.00; 1H NMR
(400 MHz, CDCl3) ∂ 0.88 (t, 36H, J=6.8, 6.8), 1.26 (m, 170H), 1.61 (m, 22H), 2.30 (t,
22H, J=7.2, 7.6), 5.12 (s, 2H), 6.89 (d, 1H, J=2.4), 6.95 (dd, 1H, J=2.4, 8.4), 7.40 (m,
6H), 7.93 (s, 1H), 8.65 (s, 1H);

13

C NMR (400MHz, CDCl3) ∂ 14.03, 22.26, 24.95,

25.39, 29.13, 29.21, 29.30, 29.37, 29.66, 30.83, 31.83, 34.11, 37.75, 51.35, 70.56, 101.88,
113.41, 113.83, 121.73, 123.87, 127.47, 128.31, 128.59, 128.72, 174.27, 206.68.

Compound 3-21
Compound 3-20 (0.1 g, 0.230 mmol) was dissolved in 0.3 mL1% HCl methanol. The
solution was cooled on ice and the vessel purged with nitrogen gas before the addition of
5% palladium on carbon (0.0005 g) catalyst. The reaction vessel was placed under
vacuum, and then backfilled with 1 atm hydrogen gas. The reaction was monitored by
TLC (Rf=0.42, 1:1 ethyl acetate in hexanes). Once TLC indicated no starting material
remained, the catalyst was filtered off and rinsed with methanol.

The filtrate was

concentrated under vacuum. Flash silica gel chromatography (0-100% ethyl acetate in
hexanes gradient) gave 28.4 mg (70% yield) of off white solid: mp 138.4-142.6°C. IR ν
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(neat)/cm-1 2851.98, 2920.44, 3145.96 (b), 3310.21; 1H NMR (400 MHz, CDCl3) ∂ 0.88
(t, 3H, J=6.8, 6.8), 1.27 (m, 6H), 1.71 (t, 1H, J=7.6, 7.6), 2.41 (t, 1H, J=7.6, 7.6), 6.81 (m,
2H), 7.37 (d, 1H, J=9.2), 7.93 (s, 1H), 8.65 (s, 1H);

13

C NMR (400 MHz, CDCl3) ∂

14.04, 22.62, 25.41, 29.16, 29.21, 29.29, 29.38, 31.82, 37.77, 103.06, 113.72, 124.03,
128.95, 157.25, 159.05; HRMS C19H25NO4 Expected: 331.1784, Found: 330.1724.

Compound 3-22
Sebacic acid methyl ester (0.0808g, 0.374 mmol) was dissolved in 0.5 mL
dichloromethane. A drop of dimethylformamide was added before the addition of oxalyl
chloride (0.0016 mL, 1.87 mmol). The reaction was stirred for one hour before the
solvent was removed by rotary evaporation. Once the acid chloride was concentrated to
an oil, it was dissolved in the necessary amount of dichloromethane before being added
dropwise to a solution of 3-18 (0.1 g, 0.374 mmol) and triethylamine (0.156 mL, 1.12
mmol) in 1.5 mL tetrahydrofuran. The coupling reaction was refluxed overnight before
being quenched by the addition of 2 mL water and a few drops of 6M HCl.
Dichloromethane was used to extract the product. The organic was dried over sodium
sulfate and concentrated under vacuum. Flash silica gel chromatography (Rf= 0.676, 1:1
ethyl acetate to hexanes) gave 63.6 mg (66% yield) of white solid: mp 123-126°C. IR ν
(neat)/cm-1 2850.75, 2921.49, 3032.86 (w), 3063.75 (w), 3318.49; 1H NMR (400 MHz,
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CDCl3) ∂ 1.25-1.40 (m, 8H), 1.62 (m, 2H), 1.72 (m, 2H, 2.30 (t, 2H, J=7.2, 7.6), 2.40 (t,
2H, J=7.6, 7.6), 3.66 (s, 3H), 5.12 (s, 2H), 6.89 (d, 1H, J=2.4), 6.96 (dd, 1H, J=2.4, 8.4),
7.35-7.45 (, 6H), 7.92 (s, 1H), 8.65 (s, 1H).

Compound 3-23
Compound 3-22 (0.060 g, 0.129 mmol) was dissolved in 0.3 mL 1% HCl in methanol.
The solution was cooled on ice and purged with nitrogen gas prior to the addition of 5%
palladium on carbon catalyst (0.010 g). The reaction vessel was placed under vacuum,
and then backfilled with 1 atm hydrogen gas. The reaction was monitored by TLC
(Rf=0.64, 1:1 ethyl acetate in hexanes).

Once TLC indicated no starting material

remained, the catalyst was filtered off and rinsed with methanol.

The filtrate was

concentrated under vacuum. Flash silica gel chromatography (0-100% ethyl acetate in
hexanes gradient) gave12.9 mg (26.7% yield) of a white solid: mp 152.0-154.0°C. IR ν
(neat)/cm-1 2848.91, 2918.12, 3250.61 (b), 3316.21; 1H NMR (400 MHz, CDCl3) ∂
1/22-1.41 (m, 8H), 1.62 (m, 2H), 1.70 (m, 2H), 2.30 (t, 2H, J=7.6, 7.6), 3.66 (s, 3H) 6.81
(m, 2H, 7.37 (d, 1H J=8.8), 7.93 (s, 1H) 8.65 (s, 1H); 13C NMR (400 MHz, DMSO) ∂
24.33, 24.96, 28.31, 28.39, 28.42, 28.47, 33.24, 35.81, 41.30, 51.11, 101.91, 111.37,
120.81, 126.21, 128.92, 151.49, 157.93, 159.45, 172.84, 173.48; HRMS C20H25NO6
Expected: 375.1682, Found: 374.1625.
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Compound 3-24
Mono protection of the 2,4-dihydroxyacetophenone was carried out according to the
procedure in Jung, et al.

Eur. J. Med. Chem. 2003, 38, 537.47

The 2,4-

dihydroxyacetophenone starting material (10g, 65.7 mmol) was dissolved in 131 mL
acetonitrile. Potassium carbonate (9.99 g, 72.3 mmol) was added to the solution, and the
mixture was refluxed for one hour. After one hour, benzyl bromide (7.66 mL, 64.4
mmol) dissolved in 13.4 mL acetonitrile was added dropwise to the mixture.

The

protection reaction was then refluxed an additional 3 hours before being quenched by the
removal of the potassium carbonate. Ethyl acetate was added to the filtrate and was
washed with dilute HCl. Silica gel chromatography (20% ethyl acetate in hexanes) gave
clean product in a 98.9% yield.

1

H NMR (400 MHz, CDCl3) ∂ 2.56 (s, 3H), 5.10 (s,

2H), 6.50 (s, 1H), 6.53 (d, 1H, J=2.48), 7.30-7.47 (m, 5H), 7.64 (d, 1H, J=9.12), 12.73 (s,
1H).

Compound 3-25
Closing of the coumarin ring using the mono-protected acetophenone was carried out
according to the procedure in Lei, et al. Chin. J. Chem. 2002, 20, 1263.57 Sodium
hydride (60% in mineral oil, 0.70 g, 17.5 mmol) was suspended in 30 mL of toluene.
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Added to the suspension was 4-benzyloxy-2-hydroxyacetophenone 4-# (1.5 g, 5.9 mmol)
dissolved in 15 mL toluene. Once the basic acetophenone mixture stopped bubbling,
diethyl carbonate (1.06 mL, 8.8 mmol) in 7.5 mL toluene was added dropwise. The
reaction was refluxed overnight before being cooled to 0°C and quenched with water and
the necessary 6M HCl to bring the pH to 1. The aqueous solution was washed with ethyl
acetate multiple times to extract the product. The combined organic washes were washed
with brine and dried over sodium sulfate before being concentrated under vacuum. Flash
silica gel chromatography (0-10% methanol in dichloromethane gradient) afforded an
off-white solid with a 63% yield.

Compound 3-26
7-Benzyloxy-4-hydroxycoumarin 3-25 (0.2g, 0.745mmol) was dissolved in 3 mL
methanol. The solution was cooled on ice and the reaction vessel purged with nitrogen
gas before the addition of 5% palladium on carbon (0.01 g). The reaction vessel was
placed under vacuum, and then backfilled with 1 atm hydrogen gas. The reaction was
monitored by TLC (Rf=0.1-0.3 smear in 8% methanol in dichloromethane). Once TLC
indicated reaction was complete, the catalyst was filtered off and rinsed with methanol
until the filtrate was no longer colored. The filtrate was concentrated under vacuum.
Flash silica gel chromatography (0-10% methanol in dichloromethane gradient) gave the
white solid: mp 216°C dec., product in 98% yield. IR ν (neat)/cm-1 2599.7 (b, 2852.07,
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2920.67, 2952.66 (w); 1H NMR (400 MHz, MeOD) ∂ 5.44 (s, 1H), 6.69 (d, 1H, J=2.0),
7.79 (dd, 1H, J=2.0, 8.4), 7.73 (d, 1H, J=8.4);

13

C NMR (400 MHz, MeOD) ∂ 30.73,

103.17, 109.49, 114.11, 125.93, 157.20, 163.67, 167.04, 169.22;

HRMS C9H6O4

Expected: 178.0266, Found: 177.0193.

SPR Experimental Procedure
Linear, 5’ biotinylated DNA was dissolved in SPR buffer (10 mM HEPES pH 7.3, 3 mM
EDTA, 0.005% surfactant P20) to give a concentration of 600 nM. The DNA was
immobilized on the surface of flow cell two of a streptavidin-coated sensor chip by
flowing 50 µL of the solution through at a rate of 10 µL per minute. Flow cells one and
two were then capped with 100 µL of a 1 mg/mL solution of biotin in SPR buffer. The
BioCore T200 instrument was then primed with SPR buffer containing 1% (v/v) DMSO,
and the flow rate was increased to 50 µL/min. To test the compound’s ability to inhibit
the DNA-DNA gyrase binding interaction, a premixed solution of DNA gyrase (100 nM)
with or without compound (100 µM) was injected over flow cells one and two for 7
minutes. After allowing four minutes for dissociation, the surface of the flow cell was
regenerated using 1M NaCl in 50 mM NaOH for 30 seconds.

Supercoiling Assay Procedure
Reactions contained 50 mM Tris-HCl (pH of 8.0 at 23ºC), 10 mM MgCl2, 100 mM
potassium glutamate, 10 mM dithiothreitol, 50 µg/mL bovine serum albumin, 1 mM
ATP, 0.3 µg relaxed DNA, and 10 fmol of E. coli DNA gyrase as a tetramer.

Each

reaction also contained one of the compounds from chapter 3 at a concentration of 100
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µm. The reactions were mixed and then heated at 37ºC for 5 minutes before being
quenched by the addition of EDTA. Once EDTA was added, the reaction was allowed to
incubate for an additional 5 minutes. The reaction products were then analyzed via
agarose gel electrophoresis and run through a vertical 1.2% SeaKem ME agarose gel at 2
V/cm. The gel was run for 15 hours in a 50 mM Tris-HCl (pH 7.9 at 23ºC), 40 mM
sodium actate, and 1 mM EDTA (TAE buffer). To analyze the gel, it was then stained
with ethidium bromide and photographed.
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APPENDIX
NMR Spectra
Compound 3-2

87

88

Compound 3-3

89

Compound 3-4

90

Compound 3-5

91

Compound 3-6

92

Compound 3-7

93

Compound 3-8

94

Compound 3-9

95

Compound 3-11

96

Compound 3-12

97

Compound 3-13

We were unable to obtain a carbon NMR spectrum for this compound.
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Compound 3-19
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Compound 3-20
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Compound 3-22

102

Compound 3-23
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Compound 3-26
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SPR Sensorgrams

3-1

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.
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3-2

Observation:

Sensorgram shows no response after addition of DNA gyrase and

compound, and looks closer to that of SD8 and DNA gyrase.
Conclusion: Inhibits DNA gyrase binding to DNA.
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3-3

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
Con tro ls :
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3-4

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
Con tro ls :
Ad ju ste d s ens or gr am - Gyr ase 100 nM
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3-5

Observation: Response after addition of DNA gyrase and compound is higher than the
negative control with only DNA gyrase.
Conclusion: This compound increases the binding interaction between DNA gyrase and
DNA.
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Con tro ls :
Ad ju ste d s ens or gr am - Gyr ase 100 nM

R U

400

200

50

0

Sam

50
-

ple

R e sp o ns e ( 0 = S am p le 1 s ta rt ) , ( 1 00 = b as e li n e)

100

R es p on s e ( 0 = Sa mp l e 1 st a rt ) , ( 1 00 = b in d i ng )

Ad jus ted se nso rg ra m - Gy ras e + S D8

R U

150

0

200
-

Sam

ple

400
-

600
-

100
800
-

150
-

1000
0

100

200

300

400
Ti m e

500

600

700

0
s

100

200

300
Ti m e

400

500

600

700
s

!

109

3-6

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
Con tro ls :
Ad ju ste d s ens or gr am - Gyr ase 100 nM
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3-7

Observation: Sensorgram’s response is not fully inhibited.
Conclusion: Partial inhibition of the DNA gyrase-DNA interaction

Adjusted sensorgram - LMG-5-54
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3-8

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
Con tro ls :
Ad ju ste d s ens or gr am - Gyr ase 100 nM
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3-9

Observation:

Sensorgram shows no response after addition of DNA gyrase and

compound, and looks closer to that of SD8 and DNA gyrase.
Conclusion: Inhibits DNA gyrase binding to DNA.

Controls:
Con tro ls :
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3-11

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
Con tro ls :
Ad ju ste d s ens or gr am - Gyr ase 100 nM
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3-12

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
Con tro ls :
Ad ju ste d s ens or gr am - Gyr ase 100 nM
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3-13

Observation: Response after addition of DNA gyrase and compound is higher than the
negative control with only DNA gyrase.
Conclusion: This compound increases the binding interaction between DNA gyrase and
DNA.

Controls:
Con tro ls :
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3-19

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
Con tro ls :
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3-21

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
Con tro ls :
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3-23

Observation:

Sensorgram shows no response after addition of DNA gyrase and

compound, and looks closer to that of SD8 and DNA gyrase.
Conclusion: Inhibits DNA gyrase binding to DNA.

Adjusted sensorgram - Gyrase+LMG-5-58
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3-26

Observation: Sensorgram nearly identical to DNA gyrase control.
Conclusion: Does not inhibit DNA gyrase binding to DNA.

Controls:
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